NASDAQ: APYX
Apyx Medical Corp Stock Forecast, Predictions & Price Target

Analyst price target for APYX

Based on 1 analyst offering 12 month price targets for Apyx Medical Corp

Min Forecast
$8.00+102.02%
Avg Forecast
$8.00+102.02%
Max Forecast
$8.00+102.02%

Should I buy or sell APYX stock?

Based on 1 analyst offering ratings for Apyx Medical Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although APYX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates APYX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their APYX stock forecasts and price targets.

APYX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-12

1 of 1

Forecast return on equity

Is APYX forecast to generate an efficient return?

Company
N/A
Industry
28.46%
Market
228.26%

Forecast return on assets

Is APYX forecast to generate an efficient return on assets?

Company
N/A
Industry
13.3%

APYX earnings per share forecast

What is APYX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.32
Avg 2 year Forecast
-$0.36
Avg 3 year Forecast
-$0.29

APYX revenue forecast

What is APYX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$52.2M+8.95%
Avg 2 year Forecast
$55.9M+16.78%
Avg 3 year Forecast
$59.8M+24.78%
APYX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APYX revenue growth forecast

How is APYX forecast to perform vs Medical Devices companies and vs the US market?

Company
7.65%
Industry
7.12%
Market
25.81%
APYX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APYX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APYX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
APYX$3.96$8.00+102.02%Buy
LUCD$1.05$4.50+328.57%Strong Buy
HSDT$3.92N/AN/A
ANIK$9.63$16.00+66.15%Buy
MXCT$1.55$6.00+287.10%Strong Buy

Apyx Medical Stock Forecast FAQ

Is Apyx Medical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: APYX) stock is to Buy APYX stock.

Out of 1 analyst, 0 (0%) are recommending APYX as a Strong Buy, 1 (100%) are recommending APYX as a Buy, 0 (0%) are recommending APYX as a Hold, 0 (0%) are recommending APYX as a Sell, and 0 (0%) are recommending APYX as a Strong Sell.

If you're new to stock investing, here's how to buy Apyx Medical stock.

What is APYX's earnings growth forecast for 2025-2027?

(NASDAQ: APYX) Apyx Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.76%.

Apyx Medical's earnings in 2025 is -$14,540,000.On average, 6 Wall Street analysts forecast APYX's earnings for 2025 to be -$12,092,090, with the lowest APYX earnings forecast at -$12,367,432, and the highest APYX earnings forecast at -$11,644,660. On average, 6 Wall Street analysts forecast APYX's earnings for 2026 to be -$13,912,405, with the lowest APYX earnings forecast at -$15,740,368, and the highest APYX earnings forecast at -$12,046,200.

In 2027, APYX is forecast to generate -$10,921,888 in earnings, with the lowest earnings forecast at -$10,493,579 and the highest earnings forecast at -$11,243,120.

What is APYX's revenue growth forecast for 2025-2027?

(NASDAQ: APYX) Apyx Medical's forecast annual revenue growth rate of 7.65% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.

Apyx Medical's revenue in 2025 is $47,902,000.On average, 6 Wall Street analysts forecast APYX's revenue for 2025 to be $1,995,845,022, with the lowest APYX revenue forecast at $1,903,796,757, and the highest APYX revenue forecast at $2,067,931,013. On average, 6 Wall Street analysts forecast APYX's revenue for 2026 to be $2,139,175,682, with the lowest APYX revenue forecast at $1,972,173,283, and the highest APYX revenue forecast at $2,328,932,015.

In 2027, APYX is forecast to generate $2,285,795,146 in revenue, with the lowest revenue forecast at $2,196,156,120 and the highest revenue forecast at $2,353,024,415.

What is APYX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: APYX) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 13.3%.

What is APYX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year APYX price target, the average APYX price target is $8.00, with the highest APYX stock price forecast at $8.00 and the lowest APYX stock price forecast at $8.00.

The Wall Street analyst predicted that Apyx Medical's share price could reach $8.00 by Nov 12, 2026. The average Apyx Medical stock price prediction forecasts a potential upside of 102.02% from the current APYX share price of $3.96.

What is APYX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: APYX) Apyx Medical's current Earnings Per Share (EPS) is -$0.36. On average, analysts forecast that APYX's EPS will be -$0.32 for 2025, with the lowest EPS forecast at -$0.32, and the highest EPS forecast at -$0.30. On average, analysts forecast that APYX's EPS will be -$0.36 for 2026, with the lowest EPS forecast at -$0.41, and the highest EPS forecast at -$0.32. In 2027, APYX's EPS is forecast to hit -$0.29 (min: -$0.27, max: -$0.29).

What is APYX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: APYX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.